Timing of Endoscopy in Cirrhotic Patients with Acute Variceal Bleeding

NCT06031402 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 368

Last updated 2025-02-27

No results posted yet for this study

Summary

Endoscopy is important for the diagnosis and treatment of acute upper gastrointestinal bleeding (AUGIB), especially acute variceal bleeding (AVB), in patients with liver cirrhosis. However, the optimal timing of endoscopy remains controversial, primarily because the currently available evidence is of poor quality, and the definition of early endoscopy is also very heterogeneous among studies. Herein, a multicenter randomized controlled trial (RCT) is performed to explore the impact of timing of endoscopy on the outcomes of cirrhotic patients with AVB.

Conditions

  • Acute Upper Gastrointestinal Bleeding
  • Acute Variceal Bleeding

Interventions

PROCEDURE

Endoscopy

Endoscopy

Sponsors & Collaborators

  • General Hospital of Shenyang Military Region

    lead OTHER

Principal Investigators

  • Xingshun Qi, MD · General Hospital of Shenyang Military Area

  • Yiling Li, MD · First Hospital of China Medical University

  • Bimin Li, MD · The First Affiliated Hospital of Nanchang University

  • Xuefeng Luo, MD · West China Hospital

  • Xiaofeng Liu, MD · The 960th Hospital of the Chinese People's Liberation Army

  • Chunqing Zhang, MD · Affiliated Provincial Hospital of Shandong First Medical University

  • Mingkai Chen, MD · People's Hospital of Wuhan University

  • Derun Kong, MD · The First Affiliated Hospital of Anhui Medical University

  • Fernando G Romeiro, MD · Botucatu Medical School

  • Andrea Mancuso, MD · Azienda di Rilievo Nazionale ad Alta Specializzazione Civico-Di Cristina-Benfratelli

  • Nahum Méndez-Sánchez, MD · Medica Sur Clinic and Foundation

  • Enqiang Linghu, MD · The First Medical Center of Chinese PLA General Hospital

  • Yunhai Wu, MD · The Sixth People's Hospital of Shenyang

  • Metin Basaranoglu, MD · Bezmialem Vakif University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-04
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06031402 on ClinicalTrials.gov